General Nuclear Medicine Track

The general nuclear medicine track features a wide-ranging scope of sessions developed and led by experts from SNMMI's specialty councils and centers of excellence. These sessions are designed to expand your knowledge on the latest clinical applications and best practices in the field advancing precision medicine.

Thursday, January 26

1:30–3:30 pm PT

Artificial Intelligence in Nuclear Cardiology
Sponsored by the SNMMI Cardiovascular Council
Organizer: Piotr J. Slomka, PhD
Moderators: Piotr J. Slomka, PhD; Chi Liu, PhD

Session Description
Several key technologies are being developed for nuclear cardiology and here based on artificial intelligence. These techniques include image enhancement and reconstruction, Attenuation correction, automatic segmentation, and diagnostic support. we will outline the proposed technologies and discuss their potential added value as compared to standard practice.

Session Objectives

  • Explain methods for attenuation correction, reconstruction, and image enhancement with AI
  • Review techniques for automatic segmentation of cardiac images by AI
  • Describe the potential of diagnostic and risk stratification improvements offered by AI techniques.

Presentations

Deep Learning for Nuclear Cardiology
Piotr J. Slomka, PhD; Cedars-Sinai Medical Center

AI-Powered Data Reconstruction
Chi Liu, PhD; Yale University

AI Value for the Nuclear Cardiologist
Robert Miller, MD, University of Calgary

Risk Stratification with AI in Cardiovascular Imaging
Michelle Williams, MBChB, University of Edinburgh

 

3:45–5:45 pm PT

Correlative Imaging in Oncology with Special Focus on PSMA-PET/MRI and Lu-177 PSMA Therapy
Sponsored by the SNMMI PET Center of Excellence
Organizers: Farrokh Dehdashti, MD; Simindokht Dadparvar, MD, FACNM, FSNMMI
Moderators: Farrokh Dehdashti, MD; Simindokht Dadparvar, MD, FACNM, FSNMMI

Session Description
PSMA radiotracers have been approved for initial imaging and detection of recurrent disease, this session will review MRI of the prostate & significance of it combined with PSMA PET in diagnosis of prostate cancer & metastasis. In addition, the use of PET/MR in evaluation of novel agents and response to local treatment in prostate cancer will be discussed.

Session Objectives

  • Describe the complementary role of PSMA PET and prostate MRI, and the added value of hybrid PET/MRI imaging, for initial staging of prostate cancer.
  • Recognize potential additional indications for PSMA PET/MRI for prostate cancer, beyond initial staging.
  • Identify complementary roles of PSMA and GRPR PET/MRI for evaluation of intermediate- and high-risk prostate cancer prior to prostatectomy.
  • Identify exploratory roles of PSMA and GRPR PET/MRI for biopsy guidance of suspected prostate cancer and for local therapy guidance/evaluation of response

Presentations

PSMA PET/MRI for Prostate Cancer with Focus on Initial Staging
Nadine Mallak, MD

PET/MRI in Prostate Cancer – Exploring Beyond PSMA
Andrei H. Iagaru, MD, FACNM

6:30–8:30 pm PT

PSMA RPT: Clinical Trials and Practice
Sponsored by the SNMMI Therapy Center of Excellence
Organizer: Hossein Jadvar, MD, PhD, MPH, MBA, FACNM, FSNMMI
Moderator: Hossein Jadvar, MD, PhD, MPH, MBA, FACNM, FSNMMI

Session Description
This 2-hour course will review the landscape of treatments that are currently available for metastatic prostate cancer including chemotherapy, immunotherapy, androgen receptor pathway inhibitors, and the recently approved PSMA-directed radiopharmaceutical therapy. The course will involve two expert speakers. A medical oncologist will review the treatment landscape. A nuclear medicine physician will focus on PSMA RPT including the details of the randomized phase 3 VISION trial that led to the approval of 177Lu-PSMA-617 as well as other ongoing PSMA-based clinical trials exploring combination or sequential therapies and potential applicability of RPT to other phases of prostate cancer. The course will be of interest to physicians, technologists, and other nuclear medicine professionals. Upon completing this course, the audience will have a better understanding of the scope of strategies directed toward treatment of metastatic prostate cancer.

Session Objectives

  • Review the landscape of medical treatments for metastatic prostate cancer.
  • Discuss the details of the VISION trial.
  • Summarize the other ongoing clinical trials with PSMA-directed radiopharmaceutical therapy.

Presentations

Landscape of Treatments for Metastatic Prostate Cancer
Vadim Koshkin, MD, University of California, San Francisco

VISION Trial and Beyond
Jeremie Calais, MD, MS, University of California, Los Angeles

Friday, January 27

8:00–10:00 am PT

Clinical PET/MRI for the Abdomen and Pelvis
Sponsored by the SNMMI PET Center of Excellence and the Correlative Imaging Council
Organizers: Nadine Mallak, MD: Simindokht Dadparvar, MD, FACNM, FSNMMI; and Patrick Veit-Haibach, MD
Moderators: Nadine Mallak, MD: Simindokht Dadparvar, MD, FACNM, FSNMMI

Session Description
The session is intended to be clinically oriented, tailored towards physicians. It focuses on PET/MRI of the abdomen and pelvis, offering helpful tips to start a clinical PET/MRI program, and discussing the role of PET/MRI for gynecologic malignancies, and as a problem-solving tool.

Session Objectives

  • Recognize the challenges that can be encountered while starting a clinical PET/MRI program, and helpful tips to address them.
  • Describe the role and added value of hybrid PET/MRI imaging in the evaluation of gynecologic malignancies.
  • Recognize potential situations and clinical scenarios for which PET/MRI can serve as a problem-solving tool.

Presentations

Practical Tips to Start a Clinical PET/MRI
Samuel Galgano, MD, University of Alabama at Birmingham

PET/MRI for Gynecologic Malignancies
Annie Packard, MD, Mayo Clinic – Rochester

PET/MRI for Problem Solving in Abdominal and Pelvic Applications
Spencer Behr, MD, University of California, San Francisco

Q&A

 

10:15 am–12:15 pm PT

Hybrid PET/CT Cardiac Imaging: Opportunities and Challenges
Sponsored by the SNMMI Cardiovascular Council
Organizers: René R. Sevag Packard, MD, PhD
Moderators: René R. Sevag Packard, MD, PhD; Matthieu Pelletier-Galarneau, MD

Session Description
Computed tomography (CT) has become an integral part of nuclear cardiology imaging, particularly PET, driven in part by significant advances in imaging technology. This session will explore the opportunities and challenges offered by hybrid PET/CT myocardial perfusion imaging. We will include the differential diagnoses of the most common and most consequential extracardiac findings. This session will cover aspects of the recent multi-society guideline document for the use of CT in hybrid nuclear/CT cardiac imaging (endorsed by SNMMI, ASNC, SCCT, and AAPM).

Session Objectives

  • Determine the clinical value of hybrid PET/CT myocardial perfusion imaging
  • Comprehend coronary CT angiography (CTA) and CTA-based cardiac segmentation to measure vessel-specific myocardial blood flow and flow reserve
  • Be aware of extracardiac findings observed during attenuation CT scans

Presentations

Clinical Value of Hybrid PET/CT Myocardial Perfusion Imaging
Mouaz Al-Mallah, MD, Houston Methodist DeBakery Heart and Vascular Center

Role of Coronary CT Angiography in Cardiac Risk Stratification
Kimberly Kallianos, MD, University of California, San Francisco

A Coronary CT Angiography/Cardiac PET Fusion Strategy for Vessel-Specific Myocardial Blood Flow Assessment
Marina Piccinelli, PhD, Emory University

Extracardiac Finding in Attenuation CT Scans
Attila Feher, MD, PhD

 

1:15–3:15 pm PT

Pediatric Renal Scintigraphy for Evaluation of Urinary Tract Obstruction – Why, When and How to do it
Sponsored by the SNMMI Pediatric Imaging Council
Organizers: Lisa J. States MD, Reza Vali MD
Moderators: Lisa J. States MD

Session Description
This course is designed to give a multi-disciplinary overview of the current practices used for the evaluation of children with concern for urinary tract obstruction. The lectures will provide a broad overview of urinary tract dilatation and include basic and complex cases. The educational focus is to provide an organized approach for evaluation of urinary tract dilatation in a variety of scenarios and to provide the urologist with the necessary information to optimize care for these children.

Session Objectives

  • Discuss how to optimize current procedures and protocols for performing renal scintigraphy with Lasix in children.
  • Generate a report that will provide the urologist with information needed to determine if surgery is necessary.
  • Provide guidance regarding follow-up imaging for evaluation of children with urinary tract dilatation.

Presentations

Urinary Tract Obstruction in the Pediatric Patient: A Urologist's Perspective
Yi Li, MD, University of California, San Francisco

Diuretic Renography in Children: Harmonization of the SNMMI and EANM Guidelines
Zvi Bar-Sever, MD, Tel Aviv University

Multimodality Imaging for Urinary Tract Obstruction- Are Renal Scintigraphy and MR Urography Complementary
J. Christopher Davis, MD, Children’s Hospital of Philadelphia

Urinary Tract Obstruction: Interesting Cases from Simple to Complex
Reza Vali, MD, MSc, Sick Kids Children’s Hospital

 

3:45–5:45 pm PT

Jeopardy Style Game to Review Important Aspects of Nuclear Medicine You Need to Know
Sponsored by the SNMMI Academic Council, Nuclear Medicine Program Directors, Advanced Associate Council, and Early Career Professionals
Organizers: Twyla B. Bartel, DO, FACNM, FSNMMI; Justin G. Peacock, MD, PhD
Moderators: Ishani Dalal, MD; Erin Grady, MD

Session Description
This “nuts and bolts” session is intended for all nuclear medicine professionals and will be presented in a more interactive format to encourage audience participation. The purpose is to provide a general review of important patient preparation, protocoling, imaging, and image interpretation of our nuclear medicine specialty. This can be utilized as a review session for trainees and also to enhance and reinforce nuclear medicine concepts to all groups in our profession. This will be presented jointly from the perspective of technologists and physicians. Part 1 will encompass PET/CT imaging. Part 2 will pertain to general nuclear imaging. A few therapy-related cases will be intertwined in the two.

Session Objectives

  • Test your knowledge of general nuclear medicine and PET/CT imaging.
  • Review patient preparation and protocoling.
  • Review radiopharmaceutical uptake and mechanisms.

Presentations

Part I: PET/CT Imaging
Twyla Bartel, DO, MBA, FACNM, FSNMMI; Erin Grady, MD, CCD, FACNM; Norman Bolus, MSPH, CNMT, FSNMMI-TS

Part II: General Nuclear Medicine
Justin Peacock, MD, PhD; Blaine Mischen, MD; Norman Bolus, MSPH, CNMT, FSNMMI-TS

Saturday, January 28

8:00–10:00 am PT

Molecular Imaging of Fever of Unknown Origin in Adults and Children
Sponsored by the SNMMMI General Clinical Nuclear Medicine Council and Pediatric Council
Organizers:  Christopher J. Palestro, MD
Moderators: Reza Vali, MD

Session Description
Molecular imaging studies are often performed as part of the diagnostic workup of these patients. Although in-vitro labeled leukocytes and gallium-67 citrate were, for many years, the mainstay of molecular imaging for FUO, fluorine-18-fluorodeoxyglucose positron emission tomography has assumed an increasingly vital role in the diagnostic workup of this entity and in most circumstances is the molecular imaging test of choice in the patient with FUO. This clinically focused session, designed for imaging specialists, technologists, and clinicians, will provide a comprehensive review of clinical aspects of FUO in adults and children, provided by adult and pediatric infectious disease specialists, as well as a guide to the most useful, cost-effective approaches to molecular imaging of FUO, based on the SNMMI’s AUC for FUO. It will conclude with a panel discussion about the SNMMI’s AUC for FUO.

Session Objectives

  • Discuss the clinical aspects of FUO in both adults and children.
  • List the strengths and limitations of molecular imaging in patients with FUO.
  • Select the most appropriate molecular imaging test for a specific patient with FUO, based on the SNMMI’s AUC for FUO.

Presentations

FUO in Adults
Sheetal Kandiah, MD, Emory University

Molecular Imaging of FUO in Adults 
Christopher J. Palestro, MD, Zucker School of Medicine at Hofstra/Northwell

FUO in Children
Sanjay Jain, MD, Johns Hopkins University
Knowlton

Molecular Imaging of FUO in Children
Barry Shulkin, MD, St. Jude Children’s Research Hospital

Panel Discussion

 

10:30 am–12:30 pm PT

Basics of Quantitative SPECT and PET
Sponsored by the SNMMI Physics, Instrumentation and Data Sciences Council
Organizers:  Robert S. Miyaoka, PhD; Chi Liu, PhD
Moderator: PhD; Chi Liu, PhD

Session Description
This session will provide a comprehensive overview of the basic components to achieve quantitative PET and SPECT to physicians, scientists, and technologists. Various corrections will be introduced, including attenuation, scatter, and partial volume effect. Quantification of Lu-177 DOTATATE and PSMA will be highlighted. Quantification methods involving tracer kinetic modeling and artificial intelligence will also be introduced. It is expected the knowledge and competence of quantitative imaging can be increased by attending this session.

Session Objectives

  • Describe the basics of PET and SPECT quantification with various corrections
  • Examine the role of quantitative imaging in radiopharmaceutical therapy, such as Lu-177 SPECT
  • Recognize the roles of tracer kinetic modeling and artificial intelligence in quantitative imaging

Presentations

Basics of Quantitative PET
Youngho Seo, PhD, University of California, San Francisco

Basics of Quantitative SPECT
Robert S. Miyaoka, PhD, University of Washington

 

1:30–3:30 pm PT

How to Keep Out of Trouble in Clinical Nuclear Medicine:  The Legal Issues
Sponsored by the SNMMI General Clinical Nuclear Medicine Council
Organizer: Darlene Metter, MD; Paul Rudolf, MD, JD
Moderator: Bennett S. Greenspan, MD, FACNM, FACR, FSNMMI

Session Description
The practice of medicine is centered on patient care which involves many stakeholders including patients, physicians, support staff, industry, healthcare entities, payers, and regulators. Navigating this system is complicated and striving for the best patient outcomes can be challenging. Despite the most dedicated efforts to achieve optimal patient care, while simultaneously maintaining compliance with rules and regulations, negative outcomes are unavoidable and at times result in litigation and/or government investigation. 

This session will address legal issues that most physicians face during their career, including medical malpractice allegations and government investigation. The session will focus on minimizing the likelihood of these events occurring by emphasizing the importance of thorough documentation in the medical record, adhering to compliance policies, following government rules and regulations, and maintaining positive relationships with patients, colleagues, and compliance monitoring organizations. Through role playing scenarios, the session will cover responses to patient complaints medical malpractice suits, allegations of improper conduct and subpoenas.

Session Objectives

  • Discuss common legal issues in clinical nuclear medicine
  • Describe the importance of a robust compliance program
  • Reduce the likelihood of a medical malpractice lawsuit
  • Recognize the appropriate response to a subpoena or civil investigative demand

 

4:00–6:00 pm PT

Emerging Developments in Theragnostics:  Featuring Young Investigators
Sponsored by the SNMMI Center for Molecular Imaging Innovation and Translation/Radiopharmaceutical Sciences Council
Organizer: Cathy Sue Cutler, PhD, FSNMMI
Moderator: Cathy Sue Cutler, PhD, FSNMMI; Michael L. Nickels,PhD

Session Description
Theragnostics involve using a diagnostic that distinguishes patients or disease type and allows selection of therapy to optimize patient outcome. Further using diagnosis to follow therapy and ensure the patient is responding. Emerging radioisotope pairs with novel ligands and targeting agents are under development and will be presented in this session by early career investigators.

Session Objectives

  • Gain knowledge on incorporation and use of novel theragnostic radionuclides
  • Gain an understanding of production of theragnostic radionuclides
  • Gain knowledge on emerging theragnostic in clinical trials

Presentations

Pre-Targeting with Alpha Emitters – Benefits, Challenges, and Prospective
David Bauer, PhD, Memorial Sloan-Kettering Cancer Center

The Need for Speed – Rapid Antibody Accumulation for Alpha or Beta Therapy
Edwin C. Pratt, Memorial Sloan-Kettering Cancer Center

Recent Advances in Radiometals for Companion Imaging Radiopharmaceuticals
Kondapa Naidu Bobba, University of California, San Francisco

Ongoing Clinical Trials in Theranostics
Courtney A. Lawhn Heath, MD, University of California San Francisco